Product details

In their search for a suitable candidate, the management of MedImmune began to target Aviron, a biopharmaceutical company based in Mountain View, California. While the company''s lead product, FluMist, helped Aviron generate $11.7 million in revenue for the first nine months of 2001, it reported a net loss of $89.2 million for the same period. The company''s goal is to become a leader in the discovery, development, manufacture, and marketing of vaccines that are safe, effective, and can be marketed to a large population. While the acquisition looked like a fairly good strategic fit for MedImmune, the financial condition of the new biotechnology firm made a decision on an offer difficult to calculate. If they were to proceed, they would need to come up with a reasonable offer sooner rather than later.